NY-ESO-1 peptide vaccine
Sponsors
National Cancer Institute (NCI), Columbia University, Herbert Irving Comprehensive Cancer Center, Ludwig Institute for Cancer Research, Roswell Park Cancer Institute
Conditions
Fallopian Tube CancerMelanoma (Skin)Ovarian CancerOvarian Cancer Stage 3Ovarian Cancer Stage IIIOvarian Cancer Stage IVPrimary Peritoneal Cavity CancerRecurrent Fallopian Tube Cancer
Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
TerminatedNCT00027911
Start: 2001-04-30End: 2005-06-30Updated: 2013-02-15
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
NCT00037037
Start: 2001-10-31Updated: 2013-12-18
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
CompletedNCT00066729
Start: 2003-06-23End: 2013-08-01Updated: 2023-10-04
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
CompletedNCT01673217
Start: 2009-04-30End: 2013-06-30Updated: 2022-08-01
Phase 2
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
CompletedNCT00020397
Start: 2000-11-30End: 2005-07-31Updated: 2013-06-19
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
CompletedNCT00079144
Start: 2004-01-31End: 2005-08-31Updated: 2013-06-19
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Not yet recruitingNCT05479045
Start: 2026-09-01End: 2028-11-01Target: 24Updated: 2026-03-16